Results From Six Pivotal Tibotec Trials, Including Head-To-Head Data, Presented At The 11th European AIDS Conference
Oct 26th 2007Drug InformationHIV / AIDS
Data from six pivotal trials investigating Tibotec HIV compounds will be presented at the 11th European AIDS Conference (EACS) in Madrid from 24-27 October 2007. Results from these and other studies examining PREZISTA? (darunavir), the company’s protease inhibitor (PI), and two of its investigational next-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), TMC125 and TMC278, will be featured in 21 abstracts, including two oral presentations and 19 posters. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
